

ON-DEMAND

Webinars

L'Oréal: Design experiments to be robust to input variation

Victor Guiller
Scientific Expertise
Engineer, L'Oréal

Video

Alga-Made Anti-Hepatitis B Antibody Binds to Human Fcγ Receptors

Gaëtan Vanier, Szymon Stelter, Jessica Vanier, Franziska Hempel, Uwe G. Maier, Patrice Lerouge, Julian Ma, and Muriel Bardor*

Microalgae are unicellular eukaryotic organisms which represent an emerging alternative to other cell biofactories commonly used to produce monoclonal antibodies. Microalgae display several biotechnological advantages such as their rapid growth rate and their phototrophic lifestyle allowing low production costs as protein expression is solar-fueled. Recently, a fully assembled recombinant IgG antibody directed against Hepatitis B surface antigen is produced and secreted in the culture medium of the diatom *Phaeodactylum tricornutum*. A biochemical characterization of this recombinant antibody demonstrated that the Asn-297 is N-glycosylated by oligomannosides. In the immune system, antibodies interact with effector molecules and cells through their Fc part and the recognition of Fcγ receptors (FcγR) which are important for inducing phagocytosis of opsonized microbes. Interactions between IgG and FcγR are influenced by the N-glycan structures present on the Asn-297. In this study, the authors characterized the binding capacity of the anti-hepatitis B recombinant IgG produced in *P. tricornutum* to two human Fcγ receptors (FcγRI and IIIa) using a cellular binding assay and surface plasmon resonance (SPR). This allowed us to demonstrate that the alga-made antibody is able to bind FcγRI with a reduced affinity and engages FcγRIIIa with 3-times higher affinity compared to a control human IgG1.

1. Introduction

Biopharmaceuticals are protein drugs that are produced recombinantly using living cells as biofactories. There are more than 200 products on the market used for therapeutic applications.^[1] Among them, monoclonal antibodies (mAbs), especially the IgG subclass, have emerged as the most rapidly growing category of biopharmaceuticals. The overall mAbs market is evaluated to


represent a total sales value of \$75.7 billion in 2013.^[1] mAbs are used for different indications with the majority (more than 85%) being prescribed for treatment of cancer, autoimmune and inflammatory diseases.^[2]

Most of the mAbs currently commercialized are produced in mammalian cell lines. Among different cell lines, CHO cells represent the actual workhorse for the pharmaceutical industry^[3] covering around 50% of the mAb production.^[4] The reason for that is their capacity to properly fold and assemble complex proteins and perform protein post-translational modifications which are similar to human ones^[3,5] and are necessary for the stability, half-life, and functionality of biopharmaceuticals.^[6] Even if productivity and yield of mammalian cell lines has increased dramatically in the past 2 decades reaching grams of recombinant protein per liter,^[7] there is still place for improving mammalian cells factories with regard to host cell line engineering, culture medium composition, vector optimization, protein secretion, yield, production cost, and potential virus contamination.^[7–11] In addition, CHO cell production appears to be expensive (50–300\$ g^{−1} of product) and sufficient to supply only current markets concentrated in North America and Western Europe with a 14 day production run.^[12]

Therefore, the challenges include developing alternative expression systems which are able to achieve improved yields, better quality for safe, effective biopharmaceuticals, or biobetters^[13,14] at a lower price, thus, facilitating patient access to biologics. For example, patients in the developing countries are heavily affected by diseases

Dr. G. Vanier[†], J. Vanier, Prof. P. Lerouge, M. Bardor
Normandie Univ, UNIROUEN
Laboratoire Glycobiologie et Matrice Extracellulaire Végétale
Rouen 76000, France
E-mail: muriel.bardor@univ-rouen.fr

Dr. S. Stelter, Prof. J. Ma
Molecular Immunology Unit, Institute for Infection and Immunity
St. George's University of London
Cranmer Terrace, London SW17 0RE, UK

 The ORCID identification number(s) for the author(s) of this article can be found under <https://doi.org/10.1002/biot.201700496>.

[†]Present address: SAS LIPOFABRIK, Parc du Mélantois, 917 rue des Saules, Lesquin 59810, France.

Dr. F. Hempel, Prof. U. G. Maier
LOEWE Center for Synthetic Microbiology
Philipps-Universität Marburg
Marburg 35032, Germany

Prof. U. G. Maier
Department of Cell Biology
Philipps-Universität Marburg
Marburg 35032, Germany

Prof. M. Bardor
Institut Universitaire de France (I.U.F.)
1, rue Descartes, Paris Cedex 05 75231, France

DOI: 10.1002/biot.201700496

like cancers and HIV which are currently treated by injection of CHO-produced mAbs. To facilitate access to these biologics, the Gate Foundation has advised that for routine treatments, the cost of mAbs should drop to less than 10\$ g⁻¹.^[15]

This should be attainable using alternative expression such as microalgae. Indeed, microalgae represent solar-powered mAbs factories^[16,17] and similar to CHO cells, microalgae represent powerful cellular platform for large-scale production of high value proteins as they produce large amount of biomass in a short period of time due to their short life cycle.^[18] In contrast to CHO cells, they have minimal nutrient requirements, thus, allowing low-cost biopharmaceuticals production.^[16] The downstream processing of recombinant proteins in microalgae is comparable to bacteria and yeast, therefore, less complicated and expensive than in CHO cells or even in whole plant production system.^[18] In addition, many species of microalgae are generally recognized as safe for human consumption,^[16] thus, increasing safety of recombinant proteins produced in this system. Several publications report successful production of recombinant mAb fragments or full mAbs in the green microalgae *Chlamydomonas reinhardtii*.^[19–22] These alga-made antibodies were demonstrated to be functional as far as their antigen binding capacity^[19–21] or capability to efficiently kill B cells in vitro^[22] are concerned. However, these antibodies were probably not glycosylated as they were produced and accumulated within the chloroplast of the *Chlamydomonas* cells which does not contain the N-glycosylation machinery.

Recently, full-length mAbs have been expressed in the diatom *Phaeodactylum tricornutum* through nuclear transformation.^[23–25] One of these mAbs is a recombinant human IgG1kappa directed against the Hepatitis B virus Antigen (HBsAg). Two versions of the mAbs were produced successfully, either with a C-terminal DDEL signal for endoplasmic reticulum (ER) retention^[23] or without for secretion within the culture medium.^[24] The culture medium secretion strategy can be potentially advantageous as it could allow easier purification of the mAb^[13,17] since *P. tricornutum* only naturally secretes tiny amounts of endogenous proteins into the culture medium.^[26]

Previous work characterized the two mAbs produced in *P. tricornutum* in detail using a glycoproteomic approach combined to nanoLC-MS/MS.^[27] The protein sequencing analyses demonstrated that the C-terminal ends of the two mAbs were intact. In addition, the cleavage of the signal peptide was proven to be homogeneous and at the correct site for the heavy chain. With respect to the light chain, an additional N-terminal peptide resulting from a cleavage after the amino acid 31 was observed. This N-terminal peptide is shorter than the expected one, which is processed after the amino acid 22, and represents about 90% of the N-terminal extremity of the light chains.^[27] The analysis have also demonstrated that the two alga-made mAbs are N-glycosylated in the heavy chain carrying oligomannoside N-glycans ranging from Man-5 to Man-9.^[27]

IgG antibodies bind to a highly diverse group of antigens through the Fab regions and also specifically interact with effector molecules and cells of the immune system through their Fc part and the recognition of Fcγ receptors (FcγRs).^[28,29]

FcγRs are cell-surface receptors specific for IgG that play pivotal roles in humoral and cellular protection against pathogen infections through various effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC),

phagocytosis, enhancement of the immune response, and others.^[30,31] Six distinct classical Fcγ receptors, that can be grouped into three classes FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16), coexist on the human immune cells.^[32] Each receptor is characterized by different binding kinetics to different IgG isotypes.^[33] Affinity of therapeutic antibodies to FcγRs affects effector cell functions and determines effectiveness of antibody therapy.^[34] Moreover, it is well established that FcγR binding is highly dependent of the N-glycan structure attached to the mAb heavy chain.^[35–39]

The binding capability of the recombinant mAbs produced in *P. tricornutum* to their specific antigen, HBsAg, has been previously evaluated using ELISA method. The results demonstrated that the recombinant mAbs produced in *P. tricornutum* were able to bind HBsAg in vitro.^[23,24] However, interaction of these alga-produced mAbs with human FcγRs has not yet been reported. Therefore, herein, such interaction was investigated. Cellular binding assays and surface plasmon resonance (SPR) was used to assess the binding kinetics of the alga-made antibodies to human FcγRs. Two representative receptors were selected for this study, FcγRI, that is well known to capture monomeric IgG1 effectively with high affinity and is involved in mediating phagocytosis, and a lower affinity FcγRIIIa that plays a major role in inducing ADCC.^[29,40,41] To the best of our knowledge, this is the first demonstration that a recombinant mAb produced in microalgae is able to bind human FcγRs. Such results is expanding the proof-of concept that microalgae are interesting cell biofactories for the production of mAbs.

2. Experimental Section

2.1. Monoclonal Antibody Production in *P. tricornutum*, Purification, and Characterization

Secreted antibody produced in *P. tricornutum* culture medium was produced as previously described in Ref. [24]. Sequences for the heavy and light chain of the human monoclonal IgG1 antibody CL4mAb (JF970211, JF970210) were cloned into the plasmid pPha-DUAL[2xNR] (JN180664) and used to stably transform *P. tricornutum* (Bohlin, University of Texas Culture Collection, strain 646) by biolistic transfection using the particle delivery system Bio-Rad Biolistic PDS-1000/He together with M10 tungsten particles and 1350 psi rupture discs. A small scale screen for the identification of antibody expressing cells was performed via Western blot.^[24] Cells were cultivated in f/2 medium and antibody expression was induced with a change of media containing 0.9 mM NaNO₃ according to Ref. [24]. After 2 days, the secreted recombinant antibody was recovered from the culture medium and concentrated with centrifugal filter columns (molecular weight cut off of 10 kDa). The sample was finally re-suspended prior to further analysis. Antibody quantification was performed as described in.^[24] The amount of anti-Hepatitis B antibody recovered was around 2 mg L⁻¹. Antibody characterization, including its N-glycosylation profile was performed using a proteomic approach combined to nanoLC-MS/MS as described previously in^[27] and are summarized in the paragraph below.

2.2. Biochemical Characterization of the Commercial Human IgG1

Human IgG1 used as a benchmark antibody in this study has been purchased from Sigma–Aldrich (IgG1, Kappa from human myeloma plasma, Sigma–Aldrich I5154). The biochemical characterization of this antibody, including N-glycosylation and oxidation status has been performed through a glycoproteomic approach identical to the alga-made antibody as described in.^[27] Heavy and light chains of the human antibody were separated on a NuPAGE Bis-Tris gel electrophoresis. The two bands corresponded, respectively, to the heavy and light chains of the antibody were excised from the gel and cut into several pieces. Then, the gel pieces were washed several times with a solution mixture composed of 0.1M NH_4HCO_3 pH 8 and 100% CH_3CN (v.v). The samples were dried down in a SpeedVac centrifuge (Thermo Fisher) for few minutes. After a reduction step with 0.1 M dithiothreitol (DTT) for 45 min at 56 °C and alkylation with 55 mM iodoacetamide (IAA) for 30 min at room temperature in the dark, proteomic-grade trypsin was added (1 µg per protein band; Promega) and placed at 4 °C during 45 min prior to an overnight incubation at 37 °C. After the protease digestion, the gel pieces were incubated subsequently in a 50% CH_3CN solution, 5% formic acid solution, 0.1 M NH_4HCO_3 , 100% CH_3CN and finally in 5% formic acid to extract the resulting peptide and glycopeptide mixture. The sample was finally dried down before further analysis using a nano-LC1200 system coupled to a QTOF 6520 mass spectrometer equipped with a nanospray source and an LC-Chip Cube interface (Agilent Technologies). Briefly, peptide and glycopeptide mixture was enriched and desalted on a 360 nL RP-C18 trap column and separated on a Polaris (3-µm particle size) C18 column (150 mm long × 75 µm inner diameter; Agilent Technologies). A 33-min linear gradient (3–75% acetonitrile in 0.1% formic acid) at a flow rate of 320 nL min^{−1} was used, and separated peptides were analyzed with a QTOF mass spectrometer. Full autoMS scans from 290 to 1700 *m/z* and autoMS/MS from 59 to 1700 *m/z* were recorded. In every cycle, a maximum of five precursors sorted by charge state (2⁺ preferred and single-charged ions excluded) were isolated and fragmented in the collision cell. Collision cell energy was automatically adjusted depending on the *m/z*. Scan speed raise based on precursor abundance (target 25 000 counts/spectrum) and precursors sorted only by abundance. Active exclusion of these precursors was enabled after three spectra within 1.5 min, and the threshold for precursor selection was set to 1000 counts.

2.3. THP-1 Cell Culture

THP-1 cells (ATCC[®] TIB202[™]) were cultivated in RPMI-1640 medium (R0883, Sigma–Aldrich) supplemented with 2 mM of L-glutamine (Gibco), 10% of fetal calf serum (Sigma) and 10 U mL^{−1} of penicillin and streptomycin (Sigma). The cells were grown at 37 °C with a 5% CO_2 in air atmosphere. The cells were grown to a final concentration of 10⁶ cells mL^{−1}. The cell concentration and viability were controlled by mixing 10 µL of cells with 10 µL of Trypan Blue and 10 µL of the mix were put in a TC20 cell counter slide (BioRad) and analyzed by a TC20

automated cell counter (BioRad). To upregulate FcγRI expression on the cell surface, the cells were incubated overnight in the culture medium complemented with 10 ng mL^{−1} of human Interferon-γ (IFN-γ) recombinantly produced in *Escherichia coli* (R&D systems, UK).

2.4. FcγRs Expression on THP-1 Cell Surfaces

THP-1 cells were harvested by centrifugation (400 RCF, 5 min) and concentrated to 2.5 × 10⁶ cells mL^{−1} in PBS with 2.5% BSA and 0.1% sodium azide (FACS buffer) in a 96-well V-bottom culture plate (Falcon[®]). The cells were incubated with 0.25 µg/test of fluorochrome-conjugated antibodies: anti-FcγRII-FITC or anti-FcγRIII-FITC (eBioscience) or with 5 µL of anti-human CD206-APC (BioLegend) as recommended by the specific supplier for 1 h on ice. To assess expression of human FcγRI, the cells were first incubated with 10 µg mL^{−1} anti-human FcγRI (R&D), washed twice in FACS buffer by centrifugation at 400 RCF for 5 min, followed by an incubation for 20 min on ice with 1:100 FITC-conjugated anti-mouse immunoglobulins (The binding site). Then, the cells were washed twice and fluorescent intensity was measured by BD FACSCanto[™] II Flow Cytometer (BD BioSciences) using BD FACSDiva[™] Software. To identify the positive signal, mean fluorescent intensity (MFI) values were compared to MFI of THP-1 cell populations treated only with the respective isotype control: mIgG1-FITC (BD Biosciences) for FcγRII and III expression, mouse-IgG1 kappa-APC (BioLegend) for CD206 expression and with FITC-conjugated anti-mouse immunoglobulins (The binding site) for FcγRI expression. Data were analyzed using FlowJo software.

2.5. THP-1 Cell Binding Assay

For the cellular binding assays, cells were harvested by centrifugation (400 RCF, 5 min) and concentrated to 2.5 × 10⁶ cells mL^{−1} in PBS with 2.5% BSA and 0.1% sodium azide (FACS buffer) in a 96-well V-bottom culture plate (Falcon[®]). The cells were incubated with serially diluted human IgG1 (IgG1, Kappa from human myeloma plasma, Sigma–Aldrich I5154) or secreted recombinant monoclonal human antibodies directed against the Hepatitis B virus surface antigen produced in *P. tricornutum*^[24,27] for 1 h on ice and the excess of antibodies was washed off twice with the FACS buffer by centrifugation at 400 RCF for 5 min. For FcγRI-blocking experiments, the cells were previously incubated with 10 µg mL^{−1} of anti-human FcγRI (R&D) for 15 min at room temperature as recommended by the supplier. The binding of hIgG1 or recombinant anti-hHBsAg samples to THP-1 cells was detected with 1:200 FITC-conjugated F(ab')₂ fragment against human immunoglobulin light and heavy chains (Jackson ImmunoResearch Laboratories, Inc.) by 20 min incubation on ice. The cells were washed twice and fluorescent intensity was measured by BD FACSCanto[™] II Flow Cytometer (BD BioSciences) using BD FACSDiva[™] Software. MFI values were obtained by accumulation of 10 000 events from two replicates. Then, the MFI were corrected by

subtracting MFI of THP-1 cell populations treated with the F(ab')₂ fragment only. Binding curves were created using non-linear curve fit (One site – Specific binding) with GraphPad Prism 6 software. Experiments have been performed at least three times independently with two technical replicates for each. Mean of the values are used to draw the curves presented on the Figure 2.

2.6. Half Maximal Effective Concentration (EC50) Determination

For the EC50 determination, two lines were drawn tangent to the lower and higher portions of the curves. Then, a perpendicular was lined to these two tangents. The midpoint on the perpendicular line was used to draw the bisecting line. EC50 corresponds to the x-axis value of the crossing point between the bisecting line and the curve.

2.7. Surface Plasmon Resonance (SPR)

Surface plasmon resonance experiments were conducted using a Biacore X100 (GE Healthcare). Soluble Protein A from *Staphylococcus aureus* recombinantly expressed in *E. coli* (Sigma) was immobilized on a CM5 sensor chip (GE Healthcare) using amine-coupling chemistry. The sensor chip surface was activated for 7 min with a 1:1 mixture of 0.1 M NHS (*N*-hydroxysuccinimide) and 0.1 M EDC (3-(*N*,*N*-dimethylamino) propyl-*N*-ethylcarbodiimide) at a flow rate of 5 $\mu\text{L min}^{-1}$. The ligand at a concentration of 25 $\mu\text{g mL}^{-1}$ in 10 mM sodium acetate, pH 4.5, was immobilized at a density of 3500 RU on both flow cells and the surface was blocked with 1 M ethanolamine-HCl pH 8.5. In a multi-cycle analysis, antibodies were captured on the Protein A surface in the flow cell 2 to a level of 240 RU or 330 RU (for Fc γ RI or Fc γ RIIIa analysis, respectively) and the flow cell 1 was left out for reference. Recombinant ectodomains of human Fc γ RI or Fc γ RIIIa-V158 (R&D) were then injected to both flow cells at the flow rate 40 $\mu\text{L min}^{-1}$ and the surface was regenerated by two 90 s injections of 10 mM glycine-HCl pH 1.5. For the binding analysis, Fc γ Rs were injected at 120 nM concentration. For kinetics/affinity evaluation, six two-fold dilutions of human Fc γ RI, starting at 60 nM and assuming molecular weight of the receptor 31.4 kDa, were used. For human Fc γ RIIIa, the six concentrations tested were in the range of 62.5–1000 nM, assuming molecular weight of the receptor 22.6 kDa. The analysis was run in 10 mM HEPES, 150 mM NaCl, 0.005% P20, pH 7.4 at 25 °C. Sensorgrams were corrected using double referencing procedure – subtracting responses from the reference surface and from zero concentration of the analyte. The data were analyzed with 1:1 binding model, or two-state reaction model for the Fc γ RIIIa–anti-HBsAg interaction, using the global data analysis option available within Biacore X100 Evaluation 2.0.1 software.

2.8. Reproducibility and Analyses of the Results

Experiments have been performed at least 3 times independently with two technical replicates for each. Mean of the values are presented. Error bars correspond to the standard error of the

mean (SEM, $n=6$). Binding curves were created using non-linear curve fit (One site – Specific binding) with GraphPad Prism 6 software.

3. Results

As Fc γ receptors are the primary mechanism by which an antibody interacts with the immune system^[29] to help neutralize and eliminate foreign invaders such as Hepatitis B virus, we decided to investigate the capacity of the recombinant anti-HBsAg antibody produced in *P. tricornutum* to bind human Fc γ Rs. Since this alga-made antibody is a recombinant human IgG1 kappa, commercially available IgG1 kappa from human myeloma plasma was used as a control and benchmark. In order to test binding of the antibodies to cell surface human Fc γ Rs, a monocytic THP-1 cell line was first characterized for the Fc γ R expression using flow cytometry.

3.1. Characterization of the Fc γ R Expression on THP1-Cells by Flow Cytometry

THP-1 cells are human monocytic cells from the peripheral blood of a 1 year old human male with acute monocytic leukemia.^[42] This cell line has been widely used as an in vitro model to study immune responses and is known to express different receptors such as Fc receptors.^[43] Expression of different Fc receptors on the cell surface of THP-1 cells was confirmed prior to the cellular binding assay with the alga-made mAb. Flow cytometric analyses performed on the THP-1 cells showed that under the culture conditions applied in this study, the THP-1 cells express CD64 (Fc γ RI) and CD32 (Fc γ RII) as previously reported.^[44] However, expression of CD16 (Fc γ RIII) could not be detected (Figure 1A). Moreover, the cells were tested for expression of the mannose receptor, CD206, and were shown to be CD206 negative. Previous study demonstrated that the alga-made anti-HBsAg antibody contains high mannose type N-glycans,^[27] therefore, the presence of mannose receptors, that can engage high-mannose structures, would complicate Fc γ R binding analysis.^[29]

In order to upregulate CD64 (Fc γ RI) on the cell surface, THP-1 cells were treated with IFN- γ as previously described.^[44] In this condition, an increase of the mean fluorescence intensity value (MFI 975) was observed as compared to the non-treated THP-1 cells (MFI 291), thus, reflecting a threefold upregulation of the expression of CD64 (Fc γ RI) whereas expression of other receptors was not affected (Figure 1B).

3.2. Fc γ RI Binding of Recombinant Anti-HBsAg mAbs Produced in *P. tricornutum*

To test the CD64 (Fc γ RI) binding capacity of the alga-made mAb, cellular assays were performed using THP-1 cells non-treated (THP) or treated (THP*) with IFN- γ , respectively (Figure 2A). The THP-1 cells were incubated in the presence of different concentrations of the recombinant human IgG1 produced in *P. tricornutum* or the control human IgG1 derived




Figure 1. Expression of FcγRs on the surface of THP-1 cells using flow cytometry analysis. Expression of CD64 (FcγRI), CD32 (FcγRII), CD16 (FcγRIII), and CD206 (Mannose receptor) were analyzed on THP-1 cells non-treated (A) and THP-1 cells treated with 10 ng mL⁻¹ of IFN-γ (B). Red histograms reflect cells incubated with either a FITC-conjugated antibody specific to FcγRI, FcγRII, FcγRIII, or an APC-conjugated antibody specific to mannose receptor. Blue histograms indicate relevant FITC or APC-conjugated isotype controls.

from human myeloma plasma. The binding curves indicate that EC₅₀ (half maximal effective concentration) for the recombinant mAb produced in *P. tricornutum* is 0.2 μg mL⁻¹ and 0.5 μg mL⁻¹ for the human IgG1. To confirm that the observed binding to THP-1 cells is related to FcγRI, the receptor

expression on the cell surface was upregulated with 10 ng mL⁻¹ of IFN-γ (THP*), which resulted in an increase of the binding signal. Similar curves were obtained for both antibodies with EC₅₀ ratio of the alga-made mAb to the human IgG1 around 3, as observed for the non-treated THP-1 cells (THP) (Figure 2A).




Figure 2. FcγRI binding of alga-made mAbs. A) Binding to FcγRI on THP-1 cells non-treated (THP) or treated (THP*) with 10 ng mL⁻¹ IFN-γ were studied for different concentrations of recombinant anti-HBSAg mAbs produced in *P. tricornutum* or of human IgG1. The presented curves represent the mean fluorescence intensity (MFI) in relation to antibody concentration in μg mL⁻¹. The EC₅₀ were determined to be 0.2 and 0.5 μg mL⁻¹ for the alga-made mAb and for the human IgG1, respectively. Error bars correspond to the standard error of the mean (SEM, *n* = 6). B) Binding to FcγRI on THP-1 cells non-treated (THP) or treated (THP*) with 10 ng mL⁻¹ IFN-γ were studied at 2 μg mL⁻¹ of recombinant anti-HBSAg mAbs produced in *P. tricornutum* or human IgG1 with or without FcγRI-blocking solution.

Fc γ RI binding was further confirmed using Fc γ RI blocking solution. As illustrated in Figure 2B, specific blocking of the receptor reduced binding of the antibodies to both treated (THP*) and non-treated (THP) THP-1 cells by half. Altogether, the results demonstrate for the first time that the alga-made mAbs are able to bind human Fc γ RI. In order to further characterize the Fc γ RI binding, kinetics and affinity of the interaction was measured in an SPR-based assay. In addition, the capacity of the alga-made mAb to bind to Fc γ RIIIa was investigated.

3.3. Kinetic and Affinity Evaluation of Alga-Made Anti-HBsAg Binding to Human Fc γ Receptors

As kinetic rates and binding affinity are critical determinants of IgG-Fc γ R interactions, we decided to determine such parameters using surface plasmon resonance based assays for binding of the alga-made antibodies to human Fc γ RI and Fc γ RIIIa. Indeed, Fc γ RI is able to bind monomeric IgG with high affinity whereas Fc γ RIIIa is a low affinity receptor involved in ADCC,^[29] therefore, being crucial for the efficacy of therapeutic antibodies such as the anti-hepatitis B antibody.^[45,46] Alga-made anti-HBsAg or human IgG1 control antibody was captured onto a Protein A surface followed by injection of recombinant human

Fc γ Rs. The observed sensorgrams demonstrate that both antibodies can effectively bind to human Fc γ RI and Fc γ RIIIa, however, with slightly different binding patterns (Figure 3 and Figure S1, Supporting Information). Affinity measurements revealed that anti-HBsAg Ab ($K_D = 330 \pm 20$ pM) has a 4.5-fold reduced affinity to Fc γ RI, as compared to the control IgG1 derived from human cells ($K_D = 73 \pm 12$ pM). However, it can engage Fc γ RIIIa with three-times higher affinity (Table 1). Kinetics evaluation further demonstrated that the reduced affinity of the antibody expressed in *P. tricornutum* to Fc γ RI results from slightly slower association and faster dissociation rate of the complex. Binding of the alga-made antibody to Fc γ RIIIa followed a more complex binding model, which was previously reported for IgG-Fc γ RIIIa interaction,^[47,48] and revealed that increased affinity to the receptor is due to the formation of a more stable complex, with slower dissociation rate (Table 1). These results demonstrate that anti-HBsAg antibody expressed in *P. tricornutum* can effectively engage both human Fc γ Rs with unique binding characteristics.

4. Discussion

In this work, we demonstrated that the recombinant human anti-hepatitis B antibody produced in the diatom *P. tricornutum* is able to bind human Fc γ Rs, including Fc γ RI,




Figure 3. Binding of anti-HBsAg antibody to recombinant human Fc γ Rs. Antibodies were captured onto a Protein A surface to the same levels followed by injection of 120 nM human Fc γ RI or Fc γ RIIIa. The binding sensorgrams demonstrate association and dissociation of antibody-Fc γ R complex for alga-made anti-HBsAg (green sensorgrams) and a control human IgG1 derived from human cells (red sensorgrams). For kinetics and affinity measurements a full range of receptor concentrations were analyzed (sensorgrams not shown).

Table 1. Kinetics and affinity measurements for algae-made anti-HBsAg antibody interaction with recombinant human FcγRs.

	K_D	k_{on1} ($10^6 M^{-1} s^{-1}$)	k_{off1} ($10^{-3} s^{-1}$)	k_{on2} (s^{-1})	k_{off2} (s^{-1})	Half-life	χ^2 (RU ²)
FcγRI							
Anti-HBsAg	330 ± 20 pM	1.14 ± 0.05	0.38 ± 0.01	–	–	30.8 ± 0.4 min	1.2 ± 0.5
Human IgG1	73 ± 12 pM	2.84 ± 0.07	0.21 ± 0.03	–	–	58.9 ± 10 min	1.6 ± 1
FcγRIIIa							
Anti-HBsAg	182 ± 11 nM	0.61 ± 0.13	167 ± 30	0.02	0.04	–	0.7 ± 0.4
Human IgG1	542 ± 13 nM	0.8 ± 0.06	433 ± 42	–	–	1.6 ± 0.2 s	0.4 ± 0.1

Binding of antibodies to human FcγRs was analyzed using 1:1 (Langmuir) binding model, except for the anti-HBsAg–FcγRIIIa interaction, where two-state reaction model was applied. Human IgG1 derived from human cells serves as a reference antibody. Affinity is reported as dissociation constant (K_D) and kinetics as association rate constant (k_{on}) and dissociation rate constant (k_{off}). For the two-state reaction, kinetics of the second reaction (k_{on2} and k_{off2}) are reported. Half-life of the antibody-receptor complex is calculated from the dissociation rate constant (k_{off}). Due to complex binding kinetics for the FcγRIIIa, the half-life of the complex cannot be determined. χ^2 describes quality of the data-model fit. Experiments have been performed at least three times independently with two technical replicates for each. Mean of the values are presented. Standard error of the mean (SEM, $n = 6$) is indicated.

and IIIa which suggests that it could be used efficiently in human therapy to induce phagocytosis and antibody-dependent cell-mediated cytotoxicity (ADCC) response. However, when compared to the human IgG1 control, affinity of the alga-made mAb is 4.5-fold lower than the one of the human IgG1 for FcγRI and three-times higher for FcγRIIIa. It is unlikely that this difference would arise from changes in the

amino acids sequence, assembly, or folding of the human and alga-made IgG1 mAbs. Previous studies demonstrated that the alga-made IgG1 mAb was correctly assembled under the H₂L₂ form.^[23,24,27] Pairwise alignment of the protein sequences of the human IgG1 and alga-made mAbs demonstrated (Figure 4) no differences in the CH1, CH2 domains, and hinge region, including the ELLGGPSV motif. The human IgG1 sequence




Figure 4. Protein sequences alignment of the Fc part of the human IgG1 used as a control (P01857-UniProtKB) in this study and of the human anti-HBsAg antibody produced in *P. tricornutum*. The alignment has been generated with EMBOSS Needle Pairwise Sequence Alignment tool using default parameters. The CH1, CH2, and CH3 domains are framed respectively with black, red, and grey squares. The N-glycosylation site and the ELLGGPSV motif which is important for FcγRs binding are highlighted in black.

was retrieved from UniProtKB database (P01857) and was experimentally confirmed using peptide mapping (79% sequence coverage; data not shown). One amino acid substitution was observed in position 284 where a D residue in the human IgG1 sequence is replaced by a V residue in the alga-made antibody. This specific acid amino is far from the ELLGPSV motif which is known to be essential for FcγRs binding (Figure 4).^[49]

Most probably, kinetics and affinity of the alga-made antibody to human FcγRs was affected by the N-linked glycans attached to the Asn297 residue in the Fc region. Indeed, the human IgG1 used in this study as a control is glycosylated with biantennary N-glycans structures, predominantly G0, G1, and G2 glycoforms (Figure 5A), which are expected for an antibody derived from human cells (Figure 5A).^[50] In contrast, the recombinant human anti-hepatitis B antibody produced in *P. tricornutum* carries a range of oligomannosides going from Man-5 to Man-9, with the Man-9 structure being the most abundant one^[27] (Figure 5B). N-glycosylation site occupancy was determined to be 90% for the human IgG1 (Figure S2, Supporting Information) and 80% for

the alga-made mAb^[27] after PNGase F deglycosylation combined with mass spectrometry analysis. Therefore, the major difference between both antibodies is the structure of the N-glycans attached to the Fc region.

Such divergences in N-glycan structures can explain the observed difference in human FcγR binding. It is well established that the N-glycosylation of mAb influence their FcγR binding capacity.^[51] Indeed, modification of N-glycan in the Fc part can change the conformation of the Fc with consequences on the antibody efficiency to bind to Fcγ receptors.^[52] In human IgG Fc, studies demonstrated that the two CH2 domains do not interact by protein-protein contacts, but instead through an interstitial region that is formed by the N-glycans attached to the conserved Asn297 of the CH2 domains.^[52] However, such structuration may present different conformers due to the accessibility and dynamic of the N-glycan itself as recently demonstrated by NMR^[53] or to N-glycan structure variation.^[54] In addition, individual sugar moieties may also directly influence the binding^[36,55] and thus the IgG biological functions. For example, as reviewed recently by Lauc




Figure 5. Comparison of the N-glycosylation of the heavy chain of the human IgG1 and the alga-made antibody. A) MS spectrum of the glycopeptide from the heavy chain of the human IgG1 used as a control. B) Summary of the N-glycosylation status of the alga-made mAb produced and secreted in the culture medium of *P. tricornutum* as described in.^[27] Glycan structures are annotated with their proposed carbohydrate structure according to the symbolic nomenclature from the Consortium for Functional Glycomics.^[76] Blue square: N-acetylglucosamine; green circle, mannose; yellow circle, galactose; red triangle, fucose.

and collaborators in 2015,^[56] the presence of a core fucosylated *N*-glycans onto the Fc part of IgG decreased the ADCC response, the agalactosylated form of this glycan induce pro-inflammatory activity of the antibody whereas the presence of a sialylated complex *N*-glycan bearing a bisecting GlcNAc would induce anti-inflammatory activity of the same antibody.^[56] It has also been previously reported that antibodies with oligomannose *N*-glycans has slightly reduced binding to FcγRI.^[57,58] In turn, they engage FcγRIIIa more efficiently, resulting in improved ADCC activity.^[58–60] Increased affinity to FcγRIIIa most probably results from lack of core fucose,^[29] rather than the presence of mannose. It was demonstrated that core fucose sterically hinders binding to FcγRIIIa^[61] and specific removal of fucose residue increases affinity to this receptor by 1–2 orders of magnitude.^[29,36,59,62,63] Increased affinity of alga-made antibodies to FcγRIIIa could bring an advantage for monoclonal antibodies that are designed to employ cellular functions like ADCC as their main mode of action. This is a common mechanism for antibodies in cancer treatment,^[64] however, the role of ADCC has also been recognized recently in therapy and prevention of some infectious diseases.^[65–68]

Future work may involve characterizing in vivo stability of the alga-made mAbs. Oligomannose *N*-glycans present in the Fc region may promote faster clearance of the antibodies from the bloodstream via macrophage mannose receptors, reducing their in vivo half-life.^[69–71] Engineering *N*-glycosylation in diatom may be undertaken for production of recombinant mAbs with humanized glycan structures, to optimize their stability, efficacy and biological function. Similar glyco-engineering efforts have already been successfully implemented in plants and moss^[72–75] which are now able to produce recombinant biopharmaceuticals with humanized *N*-glycosylation. Such developments would broaden future possibilities of using alga-based systems for production of innovative biopharmaceuticals, to-me version, or biobetters, designed for new therapeutic applications.

Abbreviations

ADCC, antibody-dependent cell-mediated cytotoxicity; Asn, asparagine; CHO, Chinese hamster oary; ER, endoplasmic reticulum; FACS, fluorescence-activated cell sorting; FcγRs, Fcγ receptors; HBsAg, hepatitis B virus antigen; IFN, interferon; IgG, immunoglobulin G; mAbs, monoclonal antibodies; MFI, mean fluorescent intensity; SPR, surface plasmon resonance.

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

GV and SS contributed equally to this work. Authors would like to thank the University of Rouen Normandie (URN) and the Institut Universitaire de France (IUF), France as well as the LOEWE Centre SYNMIKRO in Marburg, Germany for their financial support. They are also grateful to Dr. M. Rodamer, Agilent Technologies, Germany, for technical support on the mass spectrometry analysis and to Dr P. Chan,

PISSARO proteomic platform, URN, France which is co-supported by the European Union and Région Normandie. Indeed, Europe gets involved in Normandie with European Regional Development Fund (ERDF). Conceived and designed the experiments: MB, UGM, PL, and JM. Performed the experiments: GV, SS, FH, and JV. Analyzed the data: MB, FH, GV, SS, and JV. Wrote the paper: MB, GV, SS, FH, PL, UGM, and JM. All authors have read and agreed on the manuscript prior to its submission.

Conflict of interest

The authors declare no commercial or financial conflict of interest.

Keywords

ADCC, diatom, Fcγ receptor, microalgae, monoclonal antibody, *N*-glycosylation

Received: July 22, 2017

Revised: November 20, 2017

Published online: December 27, 2017

- [1] G. Walsh, *Nat. Biotechnol.* **2014**, 32, 992.
- [2] J. G. Elvin, R. G. Couston, C. F. van der Walle, *Int. J. Pharm.* **2013**, 440, 83.
- [3] P. Hossler, S. F. Khattak, Z. J. Li, *Glycobiology* **2009**, 19, 936.
- [4] A. L. Demain, P. Vaishnav, *Biotechnol. Adv.* **2009**, 27, 297.
- [5] K. P. Jayapal, K. F. Wlaschin, W. Hu, M. G. Yap, *Chem. Eng. Prog.* **2007**, 103, 40.
- [6] N. Lingg, P. Zhang, Z. Song, M. Bardor, *Biotechnol. J.* **2012**, 7, 1462.
- [7] F. M. Wurm, *Nat. Biotechnol.* **2004**, 22, 1393.
- [8] A. J. Dickson, *Curr. Opin. Biotechnol.* **2014**, 30, 73.
- [9] R. Haryadi, S. Ho, Y. J. Kok, H. X. Pu, L. Zheng, N. A. Pereira, B. Li, X. Bi, L. T. Goh, Y. Yang, Z. Song, *PLoS ONE* **2015**, 10, e0116878.
- [10] L. Kober, C. Zehe, J. Bode, *Biotechnol. Bioeng.* **2013**, 110, 1164.
- [11] B. Stern, L. C. Olsen, C. Tröbe, H. Ravneberg, I. F. Pryme, *Trends Cell. Mol. Biol.* **2007**, 2, 1.
- [12] B. Kelley, *IMAbs* **2009**, 1, 440.
- [13] E. Mathieu-Rivet, M.-C. Kiefer-Meyer, G. Vanier, C. Ovide, C. Burel, P. Lerouge, M. Bardor, *Front. Plant Sci.* **2014**, 5, 359.
- [14] S. Rosales-Mendoza, *Algae-Made Antibodies and Immunotoxins. Algae-Based Biopharm.* Springer International Publishing, Cham **2016**, pp. 77–93.
- [15] S. W. Hadley, *ECC Conf. Integr. Contin. Biomanufacturing*. **2013**, Castelldefels, Spain.
- [16] D. J. Barrera, S. P. Mayfield, *Handbook of Microalgal Culture: Applied Phycology and Biotechnology*, 2nd ed. (Eds: A. Richmond, Q. Hu), John Wiley and Sons, Hoboken, New Jersey, USA **2013**, 2, p. 532.
- [17] F. Hempel, U. G. Maier, *Adv. Technol. Protein Complex Prod. Charact* (Ed: M. C. Vega), Springer International Publishing, Cham **2016**, vol. 896.
- [18] J. Yao, Y. Weng, A. Dickey, K. Y. Wang, *Int. J. Mol. Sci.* **2015**, 16, 28549.
- [19] S. P. Mayfield, S. E. Franklin, R. A. Lerner, *Proc. Natl. Acad. Sci. USA* **2003**, 100, 438.
- [20] M. Tran, B. Zhou, P. L. Pettersson, M. J. Gonzalez, S. P. Mayfield, *Biotechnol. Bioeng.* **2009**, 104, 663.
- [21] M. Tran, R. E. Henry, D. Siefker, C. Van, G. Newkirk, J. Kim, J. Bui, S. P. Mayfield, *Biotechnol. Bioeng.* **2013**, 110, 2826.
- [22] M. Tran, C. Van, D. J. Barrera, P. L. Pettersson, C. D. Peinado, J. Bui, S. P. Mayfield, *Proc. Natl. Acad. Sci. USA* **2013**, 110, E15.

- [23] F. Hempel, J. Lau, A. Klingl, U. G. Maier, *PLoS ONE* **2011**, 6, e28424.
- [24] F. Hempel, U. G. Maier, *Microb. Cell Fact.* **2012**, 11, 126.
- [25] F. Hempel, M. Maurer, B. Brockmann, C. Mayer, N. Biedenkopf, A. Kelterbaum, S. Becker, U. G. Maier, *Microb. Cell Fact.* **2017**, 16, 131.
- [26] C. G. Bruckner, C. Rehm, H.-P. Grossart, P. G. Kroth, *Environ. Microbiol.* **2011**, 13, 1052.
- [27] G. Vanier, F. Hempel, P. Chan, M. Rodamer, D. Vaudry, U. G. Maier, P. Lerouge, M. Bardor, *PLoS ONE* **2015**, 10, e0139282.
- [28] W. R. Strohl, L. M. Strohl, *Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry*. Elsevier, London **2012**.
- [29] J. M. Hayes, M. R. Wormald, P. M. Rudd, G. P. Davey, *J. Inflamm. Res.* **2016**, 9, 209.
- [30] J. G. J. van de Winkel, *Immunol. Lett.* **2010**, 128, 4.
- [31] J. R. Desjarlais, G. A. Lazar, *Exp. Cell. Res.* **2011**, 317, 1278.
- [32] M. Daëron, *Annu. Rev. Immunol.* **1997**, 15, 203.
- [33] P. Bruhns, B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorjoux, M. Daëron, *Blood* **2009**, 113, 3716.
- [34] S. Krapp, Y. Mimura, R. Jefferis, R. Huber, P. Sonderrmann, *J. Mol. Biol.* **2003**, 325, 979.
- [35] T. Shinkawa, K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, N. Hanai, K. Shitara, *J. Biol. Chem.* **2003**, 278, 3466.
- [36] R. L. Shields, J. Lai, R. Keck, L. Y. O'Connell, K. Hong, Y. G. Meng, S. H. Weikert, L. G. Presta, *J. Biol. Chem.* **2002**, 277, 26733.
- [37] M. Allhorn, A. I. Olin, F. Nimmerjahn, M. Collin, *PLoS ONE* **2008**, 3, e1413.
- [38] S. T. Jung, S. T. Reddy, T. H. Kang, M. J. Borrok, I. Sandlie, P. W. Tucker, G. Georgiou, *Proc. Natl. Acad. Sci. USA* **2010**, 107, 604.
- [39] M. S. Ju, S. T. Jung, *Curr. Opin. Biotechnol.* **2014**, 30, 128.
- [40] N. Bhatnagar, F. Ahmad, H. S. Hong, J. Eberhard, I.-N. Lu, M. Ballmaier, R. E. Schmidt, R. Jacobs, D. Meyer-Olson, *Eur. J. Immunol.* **2014**, 44, 3368.
- [41] W. H. Yeap, K. L. Wong, N. Shimasaki, E. C. Y. Teo, J. K. S. Quek, H. X. Yong, C. P. Diong, A. Bertoletti, Y. C. Linn, S. C. Wong, *Sci. Rep.* **2016**, 6, 34310.
- [42] S. Tsuchiya, M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, K. Tada, *Int. J. Cancer* **1980**, 26, 171.
- [43] W. Chanput, J. J. Mes, H. J. Wichers, *Int. Immunopharmacol.* **2014**, 23, 37.
- [44] H. B. Fleit, C. D. Kobasiuk, *J. Leukoc. Biol.* **1991**, 49, 556.
- [45] H. Warnatz, W. Rösch, W. Gerlich, W. Gutmann, *Clin. Exp. Immunol.* **1979**, 35, 133.
- [46] F. Bortolotti, G. Realdi, G. Diodati, G. Fattovich, *Clin. Exp. Immunol.* **1978**, 33, 211.
- [47] A. Frostell, R. Karlsson, Jerrard Hayes, M. Lindgren, P. M. Rudd, C. Annerén, *Towards an Optimized In-Vitro SPR Assay for Antibody FC Gamma Receptor Binding Kinetics*. BioPharmaceutical Emerging Best Practices Association (BEBPA)-Bioassay Conference, Lisbon, Portugal **2012**. The poster can be found here: https://www.gelifesciences.co.jp/technologies/biacore/pdf/29031593AA_FcR_poster.pdf
- [48] K.-H. Heider, K. Kiefer, T. Zenz, M. Volden, S. Stilgenbauer, E. Ostermann, A. Baum, H. Lamche, Z. Küpcü, A. Jacobi, S. Müller, U. Hirt, G. R. Adolf, E. Borges, *Blood* **2011**, 118, 4159.
- [49] J. Greenwood, M. Clark, H. Waldmann, *Eur. J. Immunol.* **1993**, 23, 1098.
- [50] L. Zhang, S. Luo, B. Zhang, *MAbs* **2016**, 8, 205.
- [51] P. Sonderrmann, A. Pincetic, J. Maamary, K. Lammens, J. V. Ravetch, *Proc. Natl. Acad. Sci. USA* **2013**, 110, 9868.
- [52] P. M. Rudd, T. Elliott, P. Cresswell, I. A. Wilson, R. A. Dwek, *Science* **2001**, 291, 2370.
- [53] A. W. Barb, J. H. Prestegard, *Nat. Chem. Biol.* **2011**, 7, 147.
- [54] I. Schwab, F. Nimmerjahn, *Nat. Rev. Immunol.* **2013**, 13, 176.
- [55] D. Houde, Y. Peng, S. A. Berkowitz, J. R. Engen, *Mol. Cell. Proteomics* **2010**, 9, 1716.
- [56] G. Lauc, M. Pezer, I. Rudan, H. Campbell, *Biochim. Biophys. Acta* **2016**, 1860, 1574.
- [57] M. Sack, A. Paetz, R. Kunert, M. Bomble, F. Hesse, G. Stiegler, R. Fischer, H. Katinger, E. Stoeger, T. Rademacher, *FASEB J.* **2007**, 21, 1655.
- [58] M. Yu, D. Brown, C. Reed, S. Chung, J. Lutman, E. Stefanich, A. Wong, J. P. Stephan, R. Bayer, *MAbs* **2012**, 4, 475.
- [59] Y. Kanda, T. Yamada, K. Mori, A. Okazaki, M. Inoue, K. Kitajima-Miyama, R. Kuni-Kamochi, R. Nakano, K. Yano, S. Kakita, K. Shitara, M. Satoh, *Glycobiology* **2007**, 17, 104.
- [60] Q. Zhou, S. Shankar, A. Roy, H. Qiu, S. Estes, A. McVie-Wylie, K. Culm-Merdek, A. Park, C. Pan, T. Edmunds, *Biotechnol. Bioeng.* **2008**, 99, 652.
- [61] C. Ferrara, S. Grau, C. Jäger, P. Sonderrmann, P. Brünker, I. Waldhauer, M. Hennig, A. Ruf, A. C. Rufer, M. Stihle, P. Umaña, J. Benz, *Proc. Natl. Acad. Sci. USA* **2011**, 108, 12669.
- [62] S. Iida, H. Misaka, M. Inoue, M. Shibata, R. Nakano, N. Yamane-Ohnuki, M. Wakitani, K. Yano, K. Shitara, M. Satoh, *Clin. Cancer Res.* **2006**, 12, 2879.
- [63] J. Jez, B. Antes, A. Castilho, M. Kainer, S. Wiederkum, J. Grass, F. Rüker, M. Woisetschlager, H. Steinkellner, *J. Biol. Chem.* **2012**, 287, 24313.
- [64] X.-R. Jiang, A. Song, S. Bergelson, T. Arroll, B. Parekh, K. May, S. Chung, R. Strouse, A. Mire-Sluis, M. Schenerman, *Nat. Rev. Drug Discov.* **2011**, 10, 101.
- [65] L. Zeitlin, J. Pettitt, C. Scully, N. Bohorova, D. Kim, M. Pauly, A. Hiatt, L. Ngo, H. Steinkellner, K. J. Whaley, G. G. Olinger, *Proc. Natl. Acad. Sci. USA* **2011**, 108, 20690.
- [66] X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando, J. B. Alimonti, H. Fausther-Bovendo, H. Wei, J. Aviles, E. Hiatt, A. Johnson, J. Morton, K. Swope, O. Bohorov, N. Bohorova, C. Goodman, D. Kim, M. H. Pauly, J. Velasco, J. Pettitt, G. G. Olinger, K. Whaley, B. Xu, J. E. Strong, L. Zeitlin, G. P. Kobinger, *Nature* **2014**, 514, 47.
- [67] A. W. Chung, M. Ghebremichael, H. Robinson, E. Brown, I. Choi, S. Lane, A. S. Dugast, M. K. Schoen, M. Rolland, T. J. Suscovich, A. E. Mahan, L. Liao, H. Streeck, C. Andrews, S. Rerks-Ngarm, S. Nitayaphan, M. S. de Souza, J. Kaewkungwal, P. Pitisuttithum, D. Francis, N. L. Michael, J. H. Kim, C. Bailey-Kellogg, M. E. Ackerman, G. Alter, *Sci. Transl. Med.* **2014**, 6, 228ra38.
- [68] J. Pollara, M. Bonsignori, M. A. Moody, M. Pazgier, B. F. Haynes, G. Ferrari, *Curr. HIV Res.* **2013**, 11, 378.
- [69] L. Alessandri, D. Ouellette, A. Acquah, M. Rieser, D. LeBlond, M. Saltarelli, C. Radziejewski, T. Fujimori, I. Correia, *MAbs* **2012**, 4, 509.
- [70] A. M. Goetze, Y. D. Liu, Z. Zhang, B. Shah, E. Lee, P. V. Bondarenko, G. C. Flynn, *Glycobiology* **2011**, 21, 949.
- [71] A. Wright, M. H. Tao, E. A. Kabat, S. L. Morrison, *EMBO J.* **1991**, 10, 2717.
- [72] A. Castilho, L. Neumann, P. Gatteringer, R. Strasser, K. Vorauer-Uhl, T. Sterovsky, A. Altmann, H. Steinkellner, *PLoS ONE* **2013**, 8, e54836.
- [73] E. L. Decker, R. Reski, *Plant Cell Rep.* **2012**, 31, 453.
- [74] M. Dicker, R. Strasser, *Expert Opin. Biol. Ther.* **2015**, 15, 1501.
- [75] R. Reski, J. Parsons, E. L. Decker, *Plant Biotechnol. J.* **2015**, 13, 1191.
- [76] A. Varki, R. D. Cummings, J. D. Esko, H. H. Freeze, P. Stanley, J. D. Marth, C. R. Bertozzi, G. W. Hart, M. E. Etzler, *Proteomics* **2009**, 9, 5398.